Correspondence to "Intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL-6-mediated protection associated with cecal microbiota changes"
- PMID: 38403937
- DOI: 10.1111/all.16075
Correspondence to "Intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL-6-mediated protection associated with cecal microbiota changes"
Comment on
-
Intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL-6-mediated protection associated with cecal microbiota changes.Allergy. 2023 May;78(5):1245-1257. doi: 10.1111/all.15606. Epub 2022 Dec 11. Allergy. 2023. PMID: 36458896 Free PMC article.
References
REFERENCES
-
- Alashkar Alhamwe B, Gao Z, Alhamdan F, et al. Intranasal administration of Acinetobacter lwoffii in a murine model of asthma induces IL‐6‐mediated protection associated with cecal microbiota changes. Allergy. 2023;78:1245‐1257.
-
- Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410.
-
- Jevnikar Z, Östling J, Ax E, et al. Epithelial IL‐6 trans‐signaling defines a new asthma phenotype with increased airway inflammation. J Allergy Clin Immunol. 2019;143:577‐590.
-
- Ilmarinen P, Tuomisto LE, Niemelä O, et al. Comorbidities and elevated IL‐6 associate with negative outcome in adult‐onset asthma. Eur Respir J. 2016;48:1052‐1062.
-
- Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin‐6 concentrations, metabolic dysfunction, and asthma severity: a cross‐sectional analysis of two cohorts. Lancet Respir Med. 2016;4:574‐584.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
